Histone Deacetylase Inhibitor II

Biochem/physiol Actions

Primary TargetHDAC

Reversible: no

Product does not compete with ATP.

Cell permeable: yes

General description

A cell-permeable second generation hybrid polar agent that acts as a histone deacetylase (HDAC) inhibitor. The HDAC inhibition is believed to arise as a result of the binding of the hydroxamic moiety to the active site zinc. Shown to be a potent inducer of transformed cell growth arrest and terminal differentiation (~4 µM). Induces apoptosis and the CD95/CD95-Ligand expression in human neuroblastoma cells, which can be blocked by Caspase Inhibitor Z-VAD-FMK (Cat. No. 627610).

A cell-permeable second generation hybrid polar agent that acts as a histone deacetylase (HDAC) inhibitor. The HDAC inhibition is believed to arise as a result of the binding of the hydroxamic moiety to the active site zinc. Shown to be a potent inducer of transformed cell growth arrest and terminal differentiation (~4 µM). Induces apoptosis and the CD95/CD95-Ligand expression in human neuroblastoma.

Legal Information

Not available for sale in the United States.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Coffey, D.C., et al. 2001. Cancer Res.61, 3591.Coffey, D.C., et al. 2000. Pediatr. Oncol.35, 577.Marks, P.A., et al. 2000. J. Natl. Cancer Inst.92, 1210.Glick, R.D., et al. 1999. Cancer Res.59, 4392.Richon, V.M., et al. 1998. Proc. Natl. Acad. Sci. USA95, 3003.Richon, V.M., et al. 1996. Proc. Natl. Acad. Sci. USA93, 5705.

Packaging

Packaged under inert gas

5 mg in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Warning

Toxicity: Standard Handling (A)